Orazio Caffo

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2026

Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 02, 2026

Beyond morphology: imaging the glioblastoma microenvironment in the era of quantitative neuro-oncology.

Journal: Frontiers in medicine

Published: April 02, 2026

Enzalutamide-Induced Host Metabolic Reprogramming Is Associated with Treatment Outcomes in Patients with Castration-Resistant Prostate Cancer: A Hypothesis-Generating Study.

Journal: Clinical pharmacology and therapeutics

Published: March 26, 2026

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Journal: Prostate cancer and prostatic diseases

Published: January 03, 2026

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.

Journal: International journal of cancer

Published: December 24, 2025

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 23, 2025

Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.

Journal: Journal of clinical medicine

Published: November 23, 2025

Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.

Journal: Cancers

Published: October 26, 2025

A report of progressive multifocal leukoencephalopathy during adjuvant abemaciclib for breast cancer.

Journal: Journal of neurovirology

Published: October 09, 2025

Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?

Journal: JCO precision oncology

Published: September 10, 2025

Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.

Journal: The oncologist

Published: July 30, 2025

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study.

Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study.

Beyond morphology: imaging the glioblastoma microenvironment in the era of quantitative neuro-oncology.

Beyond morphology: imaging the glioblastoma microenvironment in the era of quantitative neuro-oncology.

Enzalutamide-Induced Host Metabolic Reprogramming Is Associated with Treatment Outcomes in Patients with Castration-Resistant Prostate Cancer: A Hypothesis-Generating Study.

Enzalutamide-Induced Host Metabolic Reprogramming Is Associated with Treatment Outcomes in Patients with Castration-Resistant Prostate Cancer: A Hypothesis-Generating Study.

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.

Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.

Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.

Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.

A report of progressive multifocal leukoencephalopathy during adjuvant abemaciclib for breast cancer.

A report of progressive multifocal leukoencephalopathy during adjuvant abemaciclib for breast cancer.

Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?

Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?

Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.

Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.